Table 7.
Summary of Plausibility of Top 20 Results with Selected References.
| Recommendation | Interpretation |
|---|---|
| Immunoglobulins | Intravenous immunoglobulins have been evaluated as prophylactic therapy in hypogammaglobulinemic patients with lymphoproliferative disorders such as multiple myeloma [45] |
| Human leukocyte interferon | Human leukocyte interferon has been shown to have in vitro effects and multiple myeloma cell lines [46] and has been proposed as a therapeutic alternative in patients that do not tolerate therapy with other interferons |
| Interferon type ii | This interferon, also known as interferon gamma, is known to produce Beta cell activating factor, an important cell survival factor expressed by haematopoeitic cells [47] |
| Curcumina | Curcumin analogs have been shown to suppress the growth of multiple myeloma cells in vitro [48] |
| Dinoprostone | The cyclic AMP (cAMP) pathway, which is stimulated by dinoprostone (also known as prostaglandin E2) has been identified as a possible therapeutic target for multiple myeloma, as elevated cAMP kills multiple myeloma cells in vitro [49] |
| Adriamycin | Adriamycin (doxorubicin) is a component of standard treatment regimes for multiple myeloma (e.g. [50]) |
| Dexamethasonea | Dexamethasone has been evaluated as maintenance therapy for multiple myeloma [51] |
| Recombinant vascular endothelial growth factora |
Vascular endothelial growth factor is targeted by the anti-neoplastic agent Bevacizumab, which has been shown to inhibit the growth of multiple myeloma cells [52] |
| Angiotensin ii | Inhibition of angiotensin ii has been shown to augment the anti-tumor activity of other drugs in hepatocellular carcinoma. Mechanisms of action appears to include inhibition of angiogenesis, and down-regulation vascular endothelial growth factor [53]. |
| pd_98059 | pd_98059 is a MAP kinase inhibitor, and the MAP kinase pathway has been identified as a new therapeutic target for multiple myeloma [54] |
| Genistein | Genistein has been shown to inhibit the growth of multiple myeloma cells in vitro [55] |
| Serine | We were unable to identify a potential therapeutic role for this amino acid |
| Pentoxifylline | Pentoxifylline (Trental) has been shown to inhibit leukemic and lymphoma cells in vitro [56] |
| Thalidomidea | Thalidomide has been shown to be effective in clinical trials against advanced multiple myeloma [57] |
| Zinc | Zinc-alpha-2-glycoprotein is a biomarker that predicts responsiveness to thalidomide-based therapy in multiple myeloma [58] |
| Aldosterone | Suppression of aldosterone has been shown to suppress the growth of hepatocellular carcinoma. The mechanism is related to the inhibition of angiogenesis, which is an important therapeutic mechanism in multiple myeloma [57] |
| Quercetin | Quercetin has been shown to induce multiple myeloma cell death at high doses [59] |
| Rituximaba | Rituximab has been used to treat Acquired factor VIII inhibitor, a rare disorder that occurs in multiple myeloma patients [60] |
| ly294002 | Ly294002 is an inhibitor of phosphoinositide 3-kinases (PI3ks). These kinases have been shown to be important for proliferation of multiple myeloma cell lines[61] |
| Adenovirus vaccine | Adenoviral-mediated gene transfer has been shown to cause growth suppression and cytotoxicity of multiple myeloma cells in vitro [62] |
a
Occurrence in a TREATS relationship with multiple myeloma.